ADIAL PHARMACEUTICALS INC (ADIL) Stock Price & Overview
NASDAQ:ADIL • US00688A3041
Current stock price
The current stock price of ADIL is 2 USD. Today ADIL is up by 6.95%. In the past month the price decreased by -18.37%. In the past year, price increased by 171%.
ADIL Key Statistics
- Market Cap
- 2.86M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -9.91
- Dividend Yield
- N/A
ADIL Stock Performance
ADIL Stock Chart
ADIL Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to ADIL. When comparing the yearly performance of all stocks, ADIL is one of the better performing stocks in the market, outperforming 99.68% of all stocks.
ADIL Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to ADIL. ADIL scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
ADIL Earnings
ADIL Forecast & Estimates
9 analysts have analysed ADIL and the average price target is 26.52 USD. This implies a price increase of 1226% is expected in the next year compared to the current price of 2.
ADIL Groups
Sector & Classification
ADIL Financial Highlights
Over the last trailing twelve months ADIL reported a non-GAAP Earnings per Share(EPS) of -9.91. The EPS decreased by -410.82% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -119.54% | ||
| ROE | -151.19% | ||
| Debt/Equity | 0 |
ADIL Ownership
ADIL Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 25.94 | 855.344B | ||
| JNJ | JOHNSON & JOHNSON | 20.21 | 566.915B | ||
| MRK | MERCK & CO. INC. | 22.06 | 282.297B | ||
| PFE | PFIZER INC | 9.03 | 153.415B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 9.08 | 117.056B | ||
| ZTS | ZOETIS INC | 16.34 | 48.828B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 8.78 | 26.166B | ||
| VTRS | VIATRIS INC | 5.26 | 15.198B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 22.8 | 11.922B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 8.026B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 5.799B | ||
| TERN | TERNS PHARMACEUTICALS INC | N/A | 5.144B | ||
| LGND | LIGAND PHARMACEUTICALS | 24.12 | 4.084B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About ADIL
Company Profile
Adial Pharmaceuticals Inc is a US-based company operating in Pharmaceuticals industry. The company is headquartered in Charlottesville, Virginia and currently employs 5 full-time employees. The company went IPO on 2018-07-27. Adial Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The firm is focused on the development of therapies for the treatment and prevention of addiction and related disorders. The Company’s lead investigational new drug product, AD04, is a genetically targeted, serotonin-3 receptor antagonist, therapeutic agent for the treatment of Alcohol Use Disorder (AUD) in heavy drinking patients and was recently investigated in the Company’s ONWARD pivotal Phase III clinical trial for the potential treatment of AUD in subjects with certain target genotypes identified using the Company’s proprietary companion diagnostic genetic test. AD04 is also used for the treatment of other addictive disorders, such as Opioid Use Disorder, obesity, smoking, and other drug addictions. The Company’s wholly owned subsidiary is Purnovate, Inc.
Company Info
IPO: 2018-07-27
ADIAL PHARMACEUTICALS INC
1180 Seminole Trail, Suite 495
Charlottesville VIRGINIA 22901 US
CEO: William B. Stilley
Employees: 5
Phone: 14344229800
ADIAL PHARMACEUTICALS INC / ADIL FAQ
What does ADIL do?
Adial Pharmaceuticals Inc is a US-based company operating in Pharmaceuticals industry. The company is headquartered in Charlottesville, Virginia and currently employs 5 full-time employees. The company went IPO on 2018-07-27. Adial Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The firm is focused on the development of therapies for the treatment and prevention of addiction and related disorders. The Company’s lead investigational new drug product, AD04, is a genetically targeted, serotonin-3 receptor antagonist, therapeutic agent for the treatment of Alcohol Use Disorder (AUD) in heavy drinking patients and was recently investigated in the Company’s ONWARD pivotal Phase III clinical trial for the potential treatment of AUD in subjects with certain target genotypes identified using the Company’s proprietary companion diagnostic genetic test. AD04 is also used for the treatment of other addictive disorders, such as Opioid Use Disorder, obesity, smoking, and other drug addictions. The Company’s wholly owned subsidiary is Purnovate, Inc.
Can you provide the latest stock price for ADIAL PHARMACEUTICALS INC?
The current stock price of ADIL is 2 USD. The price increased by 6.95% in the last trading session.
Does ADIAL PHARMACEUTICALS INC pay dividends?
ADIL does not pay a dividend.
What is the ChartMill rating of ADIAL PHARMACEUTICALS INC stock?
ADIL has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the analyst forecast for ADIL stock?
9 analysts have analysed ADIL and the average price target is 26.52 USD. This implies a price increase of 1226% is expected in the next year compared to the current price of 2.
What is the GICS sector and industry of ADIL stock?
ADIAL PHARMACEUTICALS INC (ADIL) operates in the Health Care sector and the Pharmaceuticals industry.